New Directions in Monoclonal Antibodies: Technologies, Markets, Competition

Table of Contents

• Chapter 1. Background and Scientific Overview: Antibodies and Monoclonal Antibodies
  • 1.1. What Is an Antibody?
  • 1.2. What is a Monoclonal Antibody?
• Chapter 2. Current and Emerging Technologies: Improving Monoclonal Antibody Design and Production
  • 2.1. Key Breakthroughs in the First 30 Years of Monoclonal Antibody Development
    • -Murine-Derived Monoclonal Antibodies
    • -Chimeric Monoclonal Antibodies
    • -Humanized Monoclonal Antibodies
    • -Fully Human Monoclonal Antibodies
      • --A Dissenting View on Humanization
    • -Antibody Fragments
    • -Antibody Conjugates
  • 2.2. Monoclonal Antibody Libraries and Display Technologies
    • -Phage Display
    • -Ribosome Display
    • -Other Library-Based Technologies
  • 2.3. Other Technologies for Designing Monoclonal Antibodies
    • -New Techniques for Generating Animal-Derived Monoclonal Antibodies
    • -Humanization Technology
    • -Transgenic Mice
  • 2.4. Alternative Antibody Formats
    • -Antibody Fragments
    • -Synthetic Antibodies
    • -Bispecific Antibodies
    • -Other Antibodies That Enhance Effector Function
    • -Antibody Conjugates
  • 2.5. Technologies for Improving Monoclonal Antibody Characteristics
    • -Protein Engineering
    • -Pegylation
    • -Glycosylation
    • -Reducing Immunogenicity
    • -Alternative Modes of Administration
  • 2.6. Technologies for Improving Monoclonal Antibody Production
    • -Increasing Yields in Mammalian Cultures
    • -Transgenic Animals
    • -Transgenic Plants
• Chapter 3. Marketed and Emerging Monoclonal Antibodies: Present and Future Therapeutics and In Vivo Diagnostics
  • 3.1. Approved Therapeutic Monoclonal Antibodies
    • -Profiles of Therapeutic Monoclonal Antibodies Approved for Marketing
  • 3.2. Monoclonal Antibodies in Development for Cancer
    • -Unconjugated Monoclonal Antibodies for Cancer
    • -Anti-Idiotype Monoclonal Antibodies for Cancer
    • -Conjugated Monoclonal Antibodies for Cancer
  • 3.3. Monoclonal Antibodies in Development for Immunologic Diseases
  • 3.4. Monoclonal Antibodies in Development for Infectious Diseases
  • 3.5. Antibodies in Development for Cardiovascular Diseases
  • 3.6. Other Therapeutic Antibodies in Development
  • 3.7. Approved and Developmental Diagnostic Antibodies
    • -Profiles of Diagnostic Monoclonal Antibodies Approved for Marketing
    • -Companies Developing Diagnostic Monoclonal Antibodies
• Chapter 4. Business and Strategic Outlook: Market Potential for Monoclonal Antibodies and Trends in the Field
  • 4.1. General Trends
    • -Addressing the Manufacturing Shortfall
  • 4.2. The Market for Therapeutic Monoclonal Antibodies
    • -Cancer--Solid Tumors
    • -Cancer--Non-Hodgkins Lymphoma
    • -Immune and Inflammatory Diseases
    • -Other Emerging Markets
  • 4.3. The Market for Diagnostic Monoclonal Antibodies
  • 4.4. Company Profiles
    • -AERES Biomedical Ltd.
    • -Affibody
    • -ARIUS Research Inc.
    • -Biogen Idec
    • -BioInvent
    • -Biovation Limited
    • -Centocor, Inc.
    • -Crucell
    • -Discerna UK
    • -Domantis
    • -Epitomics, Inc.
    • -Genentech, Inc.
    • -Genmab A/S
    • -GTC Biotherapeutics
    • -Human Genome Sciences, Inc.
    • -ImmunoGen, Inc.
    • -Raven Biotechnologies, Inc.
  • 4.5. Expert Commentaries
    • -Walter Blattler, Ph.D., ImmunoGen, Inc.
    • -Carl Borrebaeck, BioInvent
    • -Rathin Das, Affitech A/S
    • -Robert Ladner, Dyax Corp.
    • -Nils Lonberg, Medarex
    • -Simon Moroney, MorphoSys
    • -Clay B. Siegall, Seattle Genetics, Inc.
    • -Stephen Worsley, Raven Biotechnologies, Inc.
    • -Geoff Yarranton, KaloBios Pharmaceuticals Inc.